Research graph
References from Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population. Local targets link to admitted publications; unresolved targets remain external evidence.
The race to make a COVID-19 vaccine
10.1016/s0140-6736(21)01902-4 · 2021 · External reference
Unresolved reference
External reference
The delta variant triggers the third wave of COVID-19 in Mexico.
2022 · External reference
Increased risk of hospitalisation and death with the delta variant in the USA
10.1016/s1473-3099(21)00685-x · 2021 · External reference
Prevalence of SARS-CoV-2 variants of concern and variants of interest in COVID-19 breakthrough infections in a hospital in Monterrey, Mexico.
10.3390/v14010154 · 2022 · External reference
Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID‐19 cases: A challenging global threat with a special focus on the Indian subcontinent
10.1002/jmv.27585 · 2022 · External reference
SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity
10.1016/j.ebiom.2023.104534 · 2023 · External reference
Unresolved reference
External reference
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
10.1016/s0140-6736(20)31605-6 · 2020 · External reference
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
2021 · External reference
SARS-CoV-2 Neutralizing antibodies: A network meta-analysis across vaccines.
10.3390/vaccines9030227 · 2021 · External reference
SARS-CoV-2 neutralizing antibodies in Mexican population: A five vaccine comparison
10.3390/diagnostics13061194 · 2023 · External reference
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
10.1016/j.cell.2021.06.020 · 2021 · External reference
Clinical and immunologic efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) vaccine in university professors during the COVID-19 Delta wave.
10.3390/vaccines10050656 · 2022 · External reference
Neutralizing activity to SARS‐CoV‐2 of convalescent and control plasma used in a randomized controlled trial
10.1111/trf.16283 · 2021 · External reference
Neutralizing antibody responses in COVID-19 convalescent sera
10.1093/infdis/jiaa673 · 2021 · External reference
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
10.1016/s0140-6736(20)31208-3 · 2020 · External reference
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions.
10.1080/21645515.2022.2068883 · 2022 · External reference
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
10.1038/s41591-021-01318-5 · 2021 · External reference
SARS-CoV-2 Antibody response in persons with past natural infection
10.1056/nejmc2103825 · 2021 · External reference
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
10.1126/science.abg9175 · 2021 · External reference
Efficacy and safety of heterologous booster vaccination after Ad5-nCoV (CanSino Biologics) vaccine: A preliminary descriptive study.
10.3390/vaccines10030400 · 2022 · External reference
Vaccine effectiveness of CanSino (Adv5-nCoV) coronavirus disease 2019 (COVID-19) vaccine among childcare workers—Mexico, March–December 2021.
10.1093/cid/ciac488 · 2022 · External reference
